# Octozi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/octozi

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.octozi.com/
- Total disclosed funding: $3M
- Latest round: Seed (May 28, 2026)
- Investors on record: 2

## About

Based in the US, Octozi, Inc. offers innovative clinical intelligence solutions that automate various clinical data workflows, enhancing operational efficiency and data accuracy for the pharmaceutical and biotechnology sectors.Founded in 2023 and headquartered in New York, US, Octozi, Inc. specializes in clinical intelligence solutions. The company has secured a total of USD 3.00 mn across two funding deals, with its latest round being a Seed round led by Surface Ventures, including investors such as Debiopharm Innovation Fund and Remarkable Ventures.Octozi offers a comprehensive clinical intelligence platform designed to automate various clinical data workflows, such as data cleaning, review, reconciliation, reporting, and clinical operations. Its five integrated AI-powered modules enable sponsors to streamline processes, improve data accuracy, and enhance operational efficiency. The platform serves pharmaceutical and biotechnology companies engaged in clinical trials, addressing needs in pharmacovigilance, clinical data management, and operational oversight across North America, Europe, and Asia.Octozi generates revenue primarily through subscription-based models for its clinical intelligence platform. Clients in the pharmaceutical and biotechnology sectors typically engage with Octozi on an annual basis, opting for multi-year subscriptions that cover various offerings such as data cleaning, safety review, documentation, and clinical assistant services. The company's AI-driven functionalities facilitate enhanced data management and reporting processes, fostering long-term relationships with its client base.Octozi, Inc. plans to leverage its recent funding to enhance its product offerings and expand into new markets. The company aims to introduce new features and modules for its clinical intelligence platform in the coming year, targeting an expansion into additional regions across Europe and Asia by 2025. The capital raised from the Seed round will support these initiatives and help in the development of innovative AI-driven solutions, further addressing the evolving needs of clients in the clinical research space.

## Funding rounds

- Seed, May 28, 2026, $3M — Surface Ventures, Remarkable Ventures

## Investors

- Surface Ventures (https://capitalatlas.ai/funds/surface-ventures) — Seed
- Remarkable Ventures (https://capitalatlas.ai/funds/remarkable-ventures) — Seed